

**Single PDL Classes containing GLP-1 Anti-Obesity Agents starting 1/1/2026:**

Drug Class	Preferred Agents	Non-Preferred Agents
<b>Anti-Obesity/Weight Loss Agents</b> ♦	benzphetamine diethylpropion <b>orlistat products:</b> orlistat <sup>2</sup> , Xenical® <sup>2</sup> phendimetrazine <b>phentermine products:</b> Adipex-P®, Lomaira®, phentermine, phentermine/topiramate	<i>liraglutide (generic for Saxenda®)</i> <sup>2</sup> [GLP1] Saxenda® ( <i>liraglutide</i> ) <sup>2</sup> [GLP1] Wegovy® ( <i>semaglutide</i> ) <sup>2</sup> [GLP1] Zepbound® ( <i>tirzepatide</i> ) <sup>2</sup> [GLP1]

**New Single PDL Classes for Zepbound® and Wegovy® other covered indications:**

Drug Class	Preferred Agents	Non-Preferred Agents
<b>GLP1s for Obstructive Sleep Apnea</b> ♦	Zepbound®♦ ( <i>tirzepatide</i> ) <sup>2</sup>	

Drug Class	Preferred Agents	Non-Preferred Agents
<b>GLP1s for Cardiovascular Risk Reduction</b> ♦		Wegovy®♦( <i>semaglutide</i> ) <sup>2</sup>

Drug Class	Preferred Agents	Non-Preferred Agents
<b>GLP1s for MASH (metabolic dysfunction-associated steatohepatitis)</b> ♦		Wegovy®♦( <i>semaglutide</i> ) <sup>2</sup>